In-vitro Study for Cerenkov Luminescence Imaging Application in Hepatic Metastasectomy

Cerenkov luminescence imaging (CLI) has been recently proposed as a method to visualize surgical margins in the operating theater, immediately after resection, allow refining surgery single procedure. Our group is preparing pilot clinical study evaluate impact of CLI during hepatic metastasectomy, using 18 F-FDG and 68 Ga-DOTATOC. Currently, we are optimizing protocol terms patient inclusion criteria, activity inject, maximum allowed delay for imaging, radiation monitoring. This paper describes preliminary have performed define protocol. The composed two branches: 1) an in-vitro predict typical signals optical attenuation liver with F Ga, 2) analysis PET/CT data determine values relevant parameters, such uptake lesion dimension. combined information by these branches gives us indication feasibility margin assessment metastasectomy. For obtained detection limits ranging from 0.55 3.5 kBq/cc, be compared minimum mean uptakes 1.6 7 respectively. F, ranged 12 145 were 5 11 From values, expect Ga able detect most patients, while activities inject sufficient signal-to-noise ratio should larger than standards, or time between injection largely reduced. results reported here can useful also more general, studies dedicated other applications liver.